Asia Pacific Anti diabetic Biosimilars Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Veröffentlicht von: precision business insights
Veröffentlicht am: 02.03.2018 11:07
Rubrik: Gesundheit & Medizin


(Presseportal openBroadcast) - Asia Pacific Anti diabetic Biosimilars Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Pressekontakt:

Asia Pacific Anti diabetic Biosimilars Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023


Asia Pacific Anti diabetic Biosimilars Market: By Drug Class (Insulin, Biguanides, Sulfonyl Ureas, Thiazolidinediones, Di Peptidyl Peptidase (DPP)-IV Inhibitors, α-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others), By Disease Type (Type-I Diabetes, Type-II Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)and Geography –Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis2012-2016 and Forecast 2017-2023

Market Outline: Asia Pacific Anti diabetic Biosimilars Market

Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/asia-pacific-anti-diabetic-biosimilars-market/#ulp-4H8Z4LpNMLEuOnnx


Market Dynamics: Asia Pacific Anti diabetic Biosimilars Market
Drivers:
• Increase in the prevalence of diabetes majorly in China and India
• Patent expiries of block buster drugs and promising product pipeline
• Rise in R&D activities for the innovation of Insulin biosimilars
Restraints:
• High cost and longer duration of R&D activities
• Stringent regulatory policies
• Complexity in development of biosimilars


To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/asia-pacific-anti-diabetic-biosimilars-market/#ulp-c654SbFYO64MsOhu

Market Scope: Asia Pacific Anti diabetic Biosimilars Market
Asia Pacificanti-diabetic biosimilars market is segmented on the basis of drug class, disease type, distribution channel, and region
Based on the drug class, Asia Pacific anti-diabetic biosimilars market is segmented into the following:
• Insulin
• Biguanides
• Sulfonyl Ureas
• Thiazolidinediones
• Di Peptidyl Peptidase (DPP)-IV Inhibitors
• α-glucosidase Inhibitos
• GLP-1 Agonists
• Others
Based on the disease type, Asia Pacific anti-diabetic biosimilars market is segmented into the following:
• Type-I Diabetes
• Type-II Diabetes
Based on the distribution channel, Asia Pacific anti diabetic biosimilars market is segmented into the following:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Based on the Country, Asia Pacific anti diabetic biosimilars market is segmented into the following:
• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific


Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/asia-pacific-anti-diabetic-biosimilars-market/#ulp-14mlyhjMGhVjZqa3

Competition Assessment: Asia Pacific Anti diabetic Biosimilars Market
Some of the players in the Asia Pacific anti-diabetic biosimilars market include:
• Biocon (India)
• Merck Sharp & Dohme Corporation (U.S.)
• Boehringer Ingelheim GmbH (Germany)
• Eli Lilly & Co. (U.S.)
• Sanofi-aventis U.S. LLC (U.S.)
• Samsung Bioepis (Samsung BioLogics) (South Korea)
• Mylan N.V. (U.S.)
• Wockhardt (India)

Key Features of the Report:
• The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
• The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
• The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
• The report tracks recent innovations, key developments and startup’s details that are actively working in the market
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
• The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market


Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/asia-pacific-anti-diabetic-biosimilars-market/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised which follow a holistic approach to solve needs of market research services based on our client needs.

Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help clients to make key decisions for business growth.

Precision Business Insights vision is to become most valued partner to fortune 500 companies by providing agile, accurate, and actionable market insights

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com






Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.